UOC
ONC

UBS O'Connor’s BeOne Medicines Ltd ONC Stock Holding History

UBS O'Connor’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-9,377
Closed -$2.27M – 470
2025
Q2 		$2.27M Buy
9,377
+7,497
+399% +$1.84M 0.06% 145
2025
Q1 		$512K Sell
1,880
-14,319
-88% -$3.35M 0.01% 221
2024
Q4 		$2.99M Buy
16,199
+9,599
+145% +$1.96M 0.07% 122
2024
Q3 		$1.48M Buy
+6,600
New +$1.19M 0.04% 223

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS O'Connor's ONC Position: Q3 2025 in Review

UBS O'Connor sold out of BeOne Medicines Ltd (ONC) in Q3 2025, closing a stake of 9,377 shares — an estimated $2.27M sold.

UBS O'Connor first reported a position in ONC in Q3 2024 and held it in 4 quarters. The position peaked at $2.99M in Q4 2024. 266 funds tracked by Wall St. Rank hold ONC as of Q3 2025.

  • UBS O'Connor reported no remaining BeOne Medicines Ltd position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 9,377 BeOne Medicines Ltd shares in Q3 2025, an estimated $2.27M.
  • UBS O'Connor first reported a position in BeOne Medicines Ltd in Q3 2024 and held it in 4 quarters.
  • UBS O'Connor's BeOne Medicines Ltd position peaked at $2.99M in Q4 2024.
  • 266 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.